Home


COVID-19: CARB-X remains open for business – virtually

CARB-X staff members are working from home. We continue to make payments to support the research programs in our portfolio, and will announce new awards as they are approved and contracts finalized.

Even as we struggle with the COVID-19 pandemic, it is critical that we continue to support the development of innovative antibiotics and other therapeutics, vaccines and diagnostics to address drug-resistant bacteria.

 


CARB-X is accelerating global antibacterial innovation by investing in the development of new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria. Our projects represent the world’s largest pre-clinical and early development pipeline of antibiotics and other therapeutics, diagnostics, microbiome and vaccines. Since CARB-X was established in July 2016, it has invested $250 million in 68 projects around the world.

250

$million

Invested

68

innovative

Projects

10

different

Countries

18

focused on new classes

Pipeline

The Challenge

Accelerate the development of novel antibiotics and other new approaches to address the emergence of drug-resistant superbugs.
Learn More


Spotlight on Science

Drug-resistant bacteria kill 700,000 people each year. The Boston Globe examines whether CARB-X can help solve the crisis.

Learn More

“Antibiotics transformed modern medicine but overuse and inappropriate use have led to dangerous bacteria developing deadly resistance. Drug discovery must go hand-in-hand with concerted action to ensure antibiotics of last resort are reserved for patients where first-line treatments will not work. And we must ensure these treatments are available in all countries for those who need them.”

— Tim Jinks, Head of Drug Resistant Infections, Wellcome Trust
Watch this video with Tim Jinks on what Wellcome Trust is doing to address the rise of drug-resistant bacteria.

Funders

ASPR
BARDA
WellcomeTrust
NIAID
UK Government

Alliance Partners

Bill and Melinda Gates Foundation

Accelerators and other partners

Events

Events

10.02.20

Boston, MA

Boston Area Antimicrobial Resistance Network (BAARN) Meeting

10.08.20

 

World Antimicrobial Resistance Congress 2020

10.15.20

 

Antimicrobial Resistance Fighter Coalition Webinar: Prevention is stronger than a cure

CARB-X News

  • 09.22.2020  |  CARB-X funds GSK to develop a new drug for urinary tract infections (UTI) caused by Escherichia coli bacteria full release

  • 08.11.2020  |  CARB-X is funding Evotec to develop a new class of broad-spectrum antibiotics to treat multidrug-resistant bacterial infections full release

  • 07.07.2020  |  CARB-X is funding Spanish biotech Vaxdyn to develop a new vaccine to prevent infections that cause life-threatening pneumonia and other deadly infections full release

See All News

In The News

  • 09.10.2020  |  Peptilogics Receives FDA Orphan Drug Designation for Novel Peptide Therapy for the Treatment of Prosthetic Joint Infections full story

  • 09.02.2020  |  A novel pre-clinical antibacterial pipeline database full story

  • 08.19.2020  |  The antibiotic paradox: why companies can’t afford to create life-saving drugs full story

See All News

Sign up for CARB-X news

Get the latest news and announcements from CARB-X.